New kits for Leica BOND RX/RXm with fluorescent readout
Leica Biosystems and Navinci collaborate to automate in situ proximity ligation assays, now with fluorescent readout.
Product launch: Naveni® CD8/MHC-I kit
Introducing Naveni® CD8/MHC-I in situ assay kit, revealing immune response intricacies. Revolutionize cancer treatment with nuanced insights, advancing precision medicine.
Expanding Your Options with NaveniLink™
Would you like to perform a proximity ligation assay using your own primary antibodies? Our NaveniLink conjugation kit allows you to do just that.
Product Advancement: NaveniFlex™ Cell
This cutting-edge kit is meticulously fine-tuned for in situ cell analysis and delivers enhanced signal strength, a shorter protocol including a separate protocol for 96-well plates.
Illuminate PD1/PD-L1 interactions – new product out!
Illuminate PD1/PD-L1 interactions – new product out! 23-06-12 Uppsala Navinci expands its portfolio to unravel PD1 signaling, introducing the fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N. With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of…
An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue
An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology we developed for NaveniFlex™ Tissue kits are tailor-made to overcome common background challenges in tissue samples. The kits are optimized for tissue samples to deliver…
Naveni pY PD1 – new in situ kit for detection of phosphorylated PD1!
Navinci has developed several in situ Proximity Ligation Assays, providing deep biological knowledge about the signaling pathways of PD1 and PD-L1. The first assay available to order is: Naveni pY PD1 (phosphorylated PD1) PD1 PD-L1 signaling has proven significant in cancer progression, and therapies with immune checkpoint inhibitors have revolutionized cancer treatment efficacy. Despite the…
Launch News – pY VEGFR2. Navinci is expanding the Naveni PTM product line.
Quantify phospho-VEGFR2 in situ Navinci is expanding the Naveni PTM product line! Quantify phosphorylated VEGFR2 with outstanding signal-to-noise ratio. Receptor tyrosine kinases (RTKs) are involved in cellular processes and altered phosphorylation states may lead to disturbed signaling pathways, tumor progression, and cancer. Specific tools for quantifying phosphorylation of RTKs in situ have been requested for…
Launch News – NaveniBright kits. Proximity Ligation Assay now with bright-field read out.
LAUNCH NEWS Navinci is taking the next step to meet the needs of the pathology field. NaveniBright is a new product line with chromogenic readout. The in situ kits are based on our Naveni Proximity Ligation Technology and significantly enhance the chromogenic signal, providing you with stronger and more accurate staining. The assay gives you detailed…
Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET
Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET We are now launching target-specific Naveni in situ proximity ligation assays for phosphorylated receptor tyrosine kinases EGFR, HER2, PDGFR-beta and MET. The assays are based on dual epitope recognition by two primary Navenibodies, that generate an amplified signal when bound in close proximity. This…